CAJ | 학술논문

目的：探讨比伐芦定应用于急性冠脉综合征(ACS)冠脉介入(PCI)患者30d时的临床疗效。方法：选择2012年2~10月收治的58例12h内出现症状、均接受急诊PCI患者为研究对象,其中36例在PCI实施前应用比伐芦定,40例患者接受普通肝素,两组患者的基线临床特征、冠脉病变情况无差异,普通肝素组使用了更多的血栓抽吸装置(P=0.04)。比较两组主要心脏不良事件发生情况。结果：两组均未有死亡、支架内血栓者。两组30d心力衰竭、因心绞痛再次住院率间差异无统计学意义(P>0.05),对照组发生严重出血1例。结论：接受PCI治疗的ACS患者中应用比伐卢定具有更好的安全性。
목적：탐토비벌호정응용우급성관맥종합정(ACS)관맥개입(PCI)환자30d시적림상료효。방법：선택2012년2~10월수치적58례12h내출현증상、균접수급진PCI환자위연구대상,기중36례재PCI실시전응용비벌호정,40례환자접수보통간소,량조환자적기선림상특정、관맥병변정황무차이,보통간소조사용료경다적혈전추흡장치(P=0.04)。비교량조주요심장불량사건발생정황。결과：량조균미유사망、지가내혈전자。량조30d심력쇠갈、인심교통재차주원솔간차이무통계학의의(P>0.05),대조조발생엄중출혈1례。결론：접수PCI치료적ACS환자중응용비벌로정구유경호적안전성。
Objective: To evaluate the efficacy of bivalirudin on ACS treated by PCI in 30 days. Methods: From Feb.2012 to Oct.2012, 35 ACS patients underwent PCI assigned to bivalirudin were matched with the other 40 patients receiving unfractioned heparin(UFH). There were no significantly different in baseline clinical characteristics and angiographic characteristics. UFH group were applied to more glycoprotein IIb/IIIa inhibitors (P=0.02). 30 days rates of bleeding and composite ischemia(death,MI,heart failure, recurrent ischemia) were compared between the two groups. Results:There were no death ,MI or stent thrombosis in two groups. 30 days heart failure, recurrent ischemia were all similar, but 2 cases of major bleeding was found in UFH group. Conclusion:In contrast with UFH,bivalirudin is more safe for the treatment of ACS patients undergoing PCI.